You are here

  • Home
  • Archive
  • Volume 73, Issue 5
  • The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines

Citation Tools

Article menu
Download PDFPDF
Original research
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Yang L, Chen M, Pu T, et al
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines
Journal of Clinical Pathology 2020;73:283-290.